In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Extends $69-Per-Share Tender Offer For Genzyme To Jan. 21

This article was originally published in The Pink Sheet Daily

Executive Summary

Less than 1% of outstanding shares had been tendered as of Dec. 10 deadline.
Advertisement

Related Content

Sanofi And Genzyme Move Closer To A Deal
Sanofi And Genzyme Move Closer To A Deal
Genzyme Builds New Manufacturing Facility As Takeover Deadline Approaches
Genzyme Builds New Manufacturing Facility As Takeover Deadline Approaches
Genzyme, Sanofi Mum On Merger Negotiations At JPM Conference
Genzyme, Sanofi Mum On Merger Negotiations At JPM Conference
Where Does Genzyme See Alemtuzumab For MS? After Gilenya, Before Tysabri
Zerhouni Moves Up At Sanofi-Aventis To President Of Global R&D
Genzyme Jumps First Consent Decree Hurdle
Genzyme Jumps First Consent Decree Hurdle

Topics

Advertisement
UsernamePublicRestriction

Register

PS071605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel